Quantum Computing Inc. spent last year selling stock into a quantum-hardware rally and spent the first half of this year converting that cash into factories, patents, and someone else's customers. The second-quarter print is the first full look at that transformation. Revenue jumped from a near-zero base a year earlier to just under $6 million, and the sequential step-up from the opening quarter is real. Almost none of that lift is the old Dirac-and-foundry story standing on its own. Three closed deals, Luminar Semiconductor in February, NuCrypt in March, and NHanced Semiconductors in the second quarter, are what put product into the income statement. The investment debate is no longer whether a pre-revenue quantum software name can survive. It is whether a cash-rich photonics roll-up can earn a return on the capital it just spent, or whether the ticker is still being priced as a quantum-computing lottery ticket sitting on a treasury.
The income statement is less kind than the revenue line. Cost of sales exceeded revenue in the quarter, producing a gross loss, which means the company is currently spending more to deliver product than customers pay. Operating expenses more than doubled to $22 million. Deal costs of about $7 million sat inside that total. The operating loss widened to $23 million. Interest income of $13 million on the remaining cash pile is what keeps the headline net loss from looking worse. That is not operating leverage. It is a money-market account subsidizing a still-unprofitable manufacturing build. Commercial breadcrumbs exist: a Dirac-3 machine landed at a global consulting firm, NeuraWave reached deployment readiness with a Planck Dynamics framework that could exceed $10 million if milestones clear, and a university ordered a quantum-secure communications system. Those are proof-of-life events, not yet a franchise.
The market still assigns a premium to the quantum brand. Shares recently changed hands near $9. That price implies a capitalization of about $2 billion. Cash and investments at mid-year still exceeded $1 billion, so the operating business is not being given away, but it is also not being ignored. First-half sales of $9 million lost money at the gross line. Management continues to describe a full-year range in the low-to-mid twenties of millions for the pre-NHanced business, plus a wide band for NHanced, and period-end backlog of $43 million is the nearest evidence that demand is more than a headline cycle. The skeptical reading is that this remains a treasury with a photonics lab attached, that government work still dominates the book, and that the newly authorized share count leaves ample room to issue stock again. The constructive reading is that Fab 2, the Luminar component line, and NeuraWave turn the cash into a vertically integrated domestic photonics supplier, with the quantum machines as a call option rather than the entire story. What decides the argument is whether gross margin turns positive and whether the backlog converts without another large equity raise.